Cereno Scientific AB (publ) publishes report from the Extraordinary General Meeting

CRNO BPörssitiedote28.10.2026 klo 13.23

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company held its Extraordinary General Meeting on October 28, 2026, at the MAQS Advokatbyrå AB’s premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairperson of the Extraordinary General Meeting (the “EGM”) was lawyer Fredrik Brusberg.

The following main resolutions were resolved upon at the EGM.

Determination of the number of directors

The EGM resolved, in accordance with the Nomination Committee's proposal, that the Board of Directors is to be comprised of six directors without deputies, for the period until the end of next Annual General Meeting.

Election of directors

The EGM resolved, in accordance with the Nomination Committee's proposal, to re-elect the directors Moi Brajanovic, Gunnar Olsson, Anders Svensson, Sten R. Sörensen, and Jeppe Øvlesen, and to elect Johan Eriksson as a new director, for the period until the end of the next Annual General Meeting. It was noted that all proposed directors had accepted their election and that the proposed composition of the Board of Directors meets the applicable requirements under the Swedish Corporate Governance Code.

Election of chairperson of the Board of Directors

The EGM resolved, in accordance with the Nomination Committee's proposal, to re-elect Jeppe Øvlesen as chairperson of the Board of Directors.

The complete proposals of the Nomination Committee are available on the company’s website, www.cerenoscientific.com.

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.